Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.

Hendin, Barry; Naismith, Robert T; Wray, Sibyl E; Huang, Deren; Dong, Qunming; Livingston, Terrie; Jones, Daniel L; Watson, Crystal; Jhaveri, Mehul

Hendin, Barry; Naismith, Robert T; Wray, Sibyl E; Huang, Deren; Dong, Qunming; Livingston, Terrie; Jones, Daniel L; Watson, Crystal; Jhaveri, Mehul.

Afiliación

Hendin B; Phoenix Neurological Associates, Phoenix, AZ, USA.
Naismith RT; Department of Neurology, Washington University School of Medicine, St Louis, MO, USA.
Wray SE; Hope Neurology MS Center, Knoxville, TN, USA.
Huang D; Mount Carmel Neuroscience and MDH Research, Westerville, OH, USA.
Dong Q; Biostatistics, Biogen, Cambridge, MA, USA.
Livingston T; US Medical, Biogen, Cambridge, MA, USA, mehul.jhaveri@biogen.com.
Jones DL; US Medical, Biogen, Cambridge, MA, USA, mehul.jhaveri@biogen.com.
Watson C; Global Value and Access, Biogen, Cambridge, MA, USA.
Jhaveri M; US Medical, Biogen, Cambridge, MA, USA, mehul.jhaveri@biogen.com.

Patient Prefer Adherence ; 12: 1289-1297, 2018.

Article en En | MEDLINE | ID: mdl-30050291

Palabras clave

TSQM; Treatment Satisfaction Questionnaire for Medication; interferon beta-1a; interferon beta-1b; patient-reported outcomes; peginterferon beta-1a; quality of life; relapsing multiple sclerosis; treatment satisfaction

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Patient Prefer Adherence Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google